(-0.04%) 5 466.98 points
(0.08%) 39 145 points
(0.20%) 17 753 points
(0.05%) $80.87
(-5.04%) $2.62
(-0.79%) $2 312.40
(-0.08%) $28.85
(3.28%) $1 018.80
(0.35%) $0.936
(0.73%) $10.68
(0.50%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States...
Stats | |
---|---|
Dagens volum | 656 224 |
Gjennomsnittsvolum | 2.02M |
Markedsverdi | 0.00 |
EPS | $-0.450 ( Q2 | 2022-08-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-25.93 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.378 (0.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-10-20 | Jain Rita | Sell | 11 600 | Restricted Stock Unit |
2022-10-20 | Herron Jennifer Lyn | Sell | 17 237 | Common Stock |
2022-10-20 | Edwards Thomas A. | Sell | 15 723 | Restricted Stock Unit |
2022-10-20 | Parker Geoffrey M. | Sell | 15 723 | Restricted Stock Unit |
2022-10-20 | Kanaya Susan M | Sell | 90 968 | Restricted Stock Unit |
INSIDER POWER |
---|
-78.69 |
Last 97 transactions |
Buy: 1 451 999 | Sell: 1 420 462 |
Volum Korrelasjon
ChemoCentryx, Inc. Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
SANB | 0.835 |
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
ChemoCentryx, Inc. Korrelasjon - Valuta/Råvare
ChemoCentryx, Inc. Økonomi
Annual | 2021 |
Omsetning: | $32.22M |
Bruttogevinst: | $31.92M (99.06 %) |
EPS: | $-1.890 |
FY | 2021 |
Omsetning: | $32.22M |
Bruttogevinst: | $31.92M (99.06 %) |
EPS: | $-1.890 |
FY | 2020 |
Omsetning: | $64.89M |
Bruttogevinst: | $64.89M (100.00 %) |
EPS: | $-0.840 |
FY | 2019 |
Omsetning: | $35.95M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.980 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.